TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05435521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body composition
Description: Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Body composition
Description: Analyze the effects of PMEP on body composition in each evaluation using an impedance threshold device

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Musculoskeletal and visceral Ultrasound
Description: Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
Study: NCT04607551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prone positionning
Description: 4 to 5 persons required for the procedure, one of them being dedicated to the management of the head of the patient, the endotracheal tube, the jugular ECMO cannula and the ventilator lines and another dedicated to the femoral ECMO cannula. The person at the head of the bed will coordinate the steps. The other persons will stand at each side of the bed. The direction of the rotation will be decided giving priority to the side of the central venous lines. The length of vascular and ventilator lines will be checked for appropriateness, the endotracheal tube and gastric tube will be secured, and the patient's knees, forehead, chest, and iliac crests will be protected using adhesive pads. The patient will be then moved along the horizontal plane to the opposite side of the bed selected for the direction of rotation. Patients will be proned at least four times during the first days on ECMO. Each prone session will stand for at least 16 hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: Patients assigned to supine will remain in a semi-recumbent position.
Study: NCT05435521

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Musculoskeletal and visceral Ultrasound
Description: Quadriceps muscle ultrasound (US) of the rectus femoris measured in each evaluation in order to analyze the effects of PMEP Visceral fat will be analyzed in each visit
Study: NCT05095389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADRCs
Description: Administration of Autologous Adipose Derived Regenerative Cells into the Diabetic Foot Ulcer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05189899

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: One hemodialysis session with virtual reality and one other without it
Study: NCT05634603

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose-free milk formula (Frisolac LF ®)
Description: Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose-free milk formula (Frisolac LF ®)
Description: Following the initial rehydration phase, children were alternately assigned to receive 100 ml/kg/day of either lactose-free or lactose-containing formula
Study: NCT05470998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Arginine
Description: L-Arginine 1000 mg free form, rapid release capsules
Study: NCT05863949

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D +/- calcium
Description: vitamin D 1000iU daily +/- calcium 500mg BID daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pill x3 daily
Study: NCT06397482

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Encapsulated Calcium Butyrate
Description: Contains at minimum 35% butyric acid
Study: NCT05648721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Datos mobile health application
Description: The mobile Health application will send women reminders to perform glucose tests and test results will be sent to the clinic personnel for evaluation. The clinic personnel will receive an alert if a woman does not send glucose charts or when there is an abnormality in the test results. In addition, women will be able to communicate with the clinic's personnel via chat, messages, phone calls, and video.

Intervention type: OTHER
Group type: OTHER
Intervention: Regular follow-up
Description: Regular follow-up according to the local clinic protocol
Study: NCT05827120

Intervention type: DEVICE
Intervention: Mechanical / pharmacomechanical thrombectomy plus local catheter directed thrombolysis
Description: * Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;~* Mechanical thrombectomy: mechanical aspiration of fresh thrombus;~* Pharmacomechanical thrombectomy (PMT): combination of mechanical disruption of the thrombus, and its aspiration, with simultaneous application of alteplase via dedicated catheter - instilation of acute/subacute thrombus with its subsequent aspiration;

Intervention type: DEVICE
Intervention: Local catheter directed thrombolysis alone
Description: - Catheter directed thrombolysis (CDT): dedicated thrombolytic catheter with side holes is placed across the acute thrombus, and slow, continuous infusion (through the catheter, or both through the catheter and sheath) of a chemical thrombolysis agent is applied - alteplase 1mg/hour plus unfractionated heparine in anticoagulation dosage;
Study: NCT05031130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empowered program integrated with family support
Description: The empowered program integrated with family support is an intervention consisted of five steps that will be given when pregnant adolescents on gestational age 32 or 33 weeks the second meeting will be when the pregnant adolescents on gestational age 34 or 35 weeks.
Study: NCT05951686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: In inhalation group, desflurane will be used for general anesthesia maintenance under the screening with Patient State Index (PSI) between a score of 25-50. Remifentanil infusion is used with desflurane with a dose of 0.05-2 mcg/ kg/ min according to PSI . Fresh gas flow is used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Remifentanil infusion will be used with a dose of 0.05-2 mcg/ kg/ min under the screening with Patient State Index (PSI) between a score of 25-50 in both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh gas
Description: Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fresh gas
Description: Fresh gas flow will be used 2 L/ min with a mixture of 50%- 50% oxygen and medical air in both groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: Propofol infusion will be used for general anesthesia maintenance with a dose of under the screening of Patient State Index (PSI) between a score of 25-50 in group tiva.
Study: NCT05604300

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E incorporated oat supplement
Description: A twice daily supplementation of Vitamin E incorporated oat for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oat supplement
Description: A twice daily supplementation of oat for 12 weeks
Study: NCT05836090

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Spirit Strengths (FSS)
Description: The FSS intervention consists of psychoeducational components that emphasize the importance of mental and emotional health as part of overall wellness, and seek to normalize experiences of stress, to de-stigmatize help-seeking, and to build hope. Core content focuses on awareness of the connections between thoughts, feelings, behaviors, and spirituality, and imparts related self-help skills. It also specifically builds in connection to culture, land and others as coping strategies. The FSS lessons were developed based on culturally adapting the Common Elements Treatment Approach (CETA).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Spirit Nurture
Description: The active control Family Spirit Nurture, is an evidence-based nutrition education curriculum that has been previously tested with Navajo communities which focuses on age-appropriate parental feeding practices, including snack routines, avoidance of sugar-sweetened beverages (SSB) and promotion of water consumption.
Study: NCT05760495

Intervention type: OTHER
Intervention: blood sampling
Description: Blood sampling for evaluation of oxidative stress markers
Study: NCT05925621

Intervention type: DRUG
Intervention: Lecanemab
Description: Observational study
Study: NCT05381688

Intervention type: PROCEDURE
Intervention: VIM DBS
Description: Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus

Intervention type: PROCEDURE
Intervention: VIM DBS
Description: Stereotactic deep brain stimulation of ventral intermediate nucleus of thalamus
Study: NCT05672264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation
Description: Consistently supervised, video-guided WB-EMS application 1.5 times per week for 28 weeks. Bipolar electric current with a frequency of 85Hz, an impulse-width of 350 µs will be used in an interval approach with 6 sec of EMS stimulation with a direct impulse boost and 4 sec of rest. Low intensity movements or exercises in a standing position were performed during the 6 s stimulation period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Six standardised physiotherapy sessions (20 min each)
Study: NCT04865653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Base oral drinking solution
Description: A moderate dose of 0.1 mg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Base solid orodispersible film
Description: A moderate dose of 0.1 mg LSD will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Tartrate oral drinking solution
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lysergic Acid Diethylamide Tartrate intravenous administration
Description: A moderate dose of 0.146 mg LSD tartrate will be administered (equivalent to 0.1 mg LSD base).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LSD Placebo
Description: Placebo for each formulation containing only the solvent or gel but no LSD.
Study: NCT05206318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Cysteamine
Description: Topical cysteamine cream applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Topical Vehicle Control
Description: Topical vehicle control cream without cysteamine active ingredients applied to the postinflammatory hyperpigmentation dark spots 15 minutes per day, followed by a face wash and moisturizing cream.
Study: NCT05307744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PS128
Description: Each PS128 capsule contained \>3 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose.
Study: NCT05716919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivaltinostat
Description: Ivaltinostat capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT06286722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive, individualized and structured exercise program
Description: See description under Arms
Study: NCT06559436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Description: Patients in the TNK treatment group will receive TNK intravenous thrombolysis after MeVO is determined, and the usual dosage for TNK intravenous thrombolysis is 0.25mg/Kg, with a maximum of 25mg,

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical management
Description: Standard medical management
Study: NCT06560359

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: F&V
Description: The intervention includes the healthy breakfast plan (daily delivery of balanced breakfast containing at least one piece of fruits, vegetables and other regular diet) and fruit box plan (weekly delivery to home). The selection of fruits and vegetables will consider seasonal availability to ensure freshness and variety. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No F&V
Description: The intervention only includes breakfast plan (daily delivery of balanced breakfast containing regular diet without fruits and vegetables) for 12 weeks. The standardized breakfast will be prepared and delivered by a professional catering service, ensuring consistency in portion size and quality. Nutrient density and adequacy will be monitored throughout the intervention period, with adjustments made as needed to maintain the nutritional integrity of the meals. Compliance will be tracked through daily logs and periodic assessments, ensuring that participants are consistently consuming the provided meals. This intervention is specifically designed to investigate the neurobehavioral impact of increased fruit and vegetable intake in a controlled and measurable manner.
Study: NCT05091138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Description: Post-operatively all patients will have an ultrasound-guided adductor canal block (ACB) with 30cc of 0.25% bupivacaine. Half of the patients (selected randomly using random number table) will receive 150mg of magnesium sulfate in the block and the other half will receive 300 mcg of buprenorphine in the block.
Study: NCT06253923

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine Hydrochloride
Description: MR-301 is an I.V. formulation for the treatment of TBI. The active ingredient is amantadine hydrochloride (HCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo for this study is 0.9% Sodium Chloride IV Solution.
Study: NCT06333964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-001
Description: AST-001, PO bid for 24weeks (dosage according to weight range)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of AST-001
Description: Placebo of AST-001, PO bid for 12 weeks + AST-001, PO bid for 12 weeks (dosage according to weight range)
Study: NCT04991584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin,Tetracycline,Furazolidone,Levofloxacin,Vonoprazan fumarate, Esomeprazole ,
Description: Patients will go through a gastroscopy and antimicrobial susceptibility test. Liver and kidney function will be monitored by blood test before and after the treatment.
Study: NCT05526768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VITLS Device
Description: VITLS remote vital sign monitoring device will be applied to consented patients so data obtained by the device can be compared to data obtained by traditional inpatient hospital monitoring devices.
Study: NCT06118320

Intervention type: DRUG
Intervention: Potassium sodium hydrogen citrate
Description: Medication: Potassium sodium hydrogen citrate granules (MADAUS GMBH, Germany, 2.5g/package).~Method: Preprandial urine pH was monitored to maintain an effective range of 6.2 to 6.8. One package should be taken after breakfast, one after lunch, and two after dinner. If the pH falls below 6.2, a half-package dose should be added; if it exceeds 6.8, a half-package dose should be reduced accordingly. Oral medication will be administered for a duration of three months.~Medication requirements: Abstain from alcohol and smoking during treatment period and avoid using any probiotics or drugs that lower uric acid levels.
Study: NCT04558827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Carbohydrate Diet
Description: Dietary choices are counseled to come primarily from lean meats, eggs, nuts, seeds, vegetables and berries.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Restricted Feeding
Description: Participants will be asked to have 2 meals within an 8 hour period, preferably before 2pm.
Study: NCT05125497

Intervention type: PROCEDURE
Intervention: In Vitro Fertilisation (IVF)
Description: Natural Cycle In Vitro Fertilisation (IVF): without hormonal stimulation Conventional In Vitro Fertilisation (IVF): conventional hormonal stimulation Minimal Stimulation In Vitro Fertilisation (IVF): low dose of hormonal stimulation will be applied
Study: NCT05256264

Intervention type: DRUG
Intervention: Ketamine
Description: Ketamine infusion at different dose to observe EEG DSA changes

Intervention type: DRUG
Intervention: Ketamine
Description: Ketamine infusion at different dose to observe EEG DSA changes
Study: NCT05384301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urban Afforestation Program
Description: An afforestation program based on land cultivation and transplantation of several plants for 90 minutes will be implemented.
Study: NCT05010967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: HIIT 3 times a week for 8 weeks. For week 1 to 4 , Warm up 5 minutes jogging in place, 6 series of 30 seconds Burpees, 30 seconds recovery, 30 seconds skipping, 30 seconds recovery, 30 seconds lunge, 30 seconds recovery, 30 seconds 1-legged squats, 30 seconds recovery, 30 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.~For week 5 to 8 , Warm up 5 minutes jogging in place, 6 series of 45 seconds Burpees, 45 seconds recovery, 45 seconds skipping, 30 seconds recovery, 45 seconds lunge, 30 seconds recovery, 45 seconds 1-legged squats, 30 seconds recovery, 45 second leg levers, 30 seconds recovery. the series will have 3 minutes rest in between. Cool down of 10 minutes with gentle stretches.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Training
Description: Yoga 3 times a week for 8 weeks. 30-50 minutes session, 5 minutes breathing, 15-35 minutes yoga poses (Cat-cow, child's pose, downward dog, plank, Cobra), followed by 10 minutes supine meditation.
Study: NCT06393959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural pulsed radiofrequency
Description: The patient lied in prone position. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a 22- gauge 150-mm RF cannula with 20 mm active tip was advanced through the sacrococcygeal ligament into the caudal epidural space under floroscopic guidence. A few milliliters contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, an electrode was connected to the cannula, and stimulation was conducted with impedance measured between 250 and 350 Ohms A different sensation or feeling such as fullness, impression, tingling, pulling or plethora at the rectal and/or coccygeal region was observed by the patients when 50 Hz was applied with 0,4 to 0,7 V sensory stimulation. No leg muscle contraction was observed with 2 Hz motor stimulation at 2 V. PRF was performed for 600 s at 5 Hz using a 5-ms pulse width at 55 V, avoiding electrode tip temperatures above 42 C.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Caudal epidural steroid enjection
Description: The patient lied in prone position and aseptic techniques were adopted. After cutaneous and subcutaneous anesthesia with 3 ml of 2% lidocaine, a spinal needle was advanced through the sacrococcygeal ligament into the caudal epidural space under fluoroscopic guidance. The needle tip was confirmed by negative aspiration for blood or cerebrospinal fluid, then a few milliliters of contrast was injected to observe the expansion of the epidural space. After correct needle placement was confirmed, a total of 10 ml mixture of saline and 8 mg dexametzone was administered into the epidural space.
Study: NCT06064331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus of 10 ml normal saline over 3 min followed by infusion of equal volume of normal saline in 20 ml syringe